Literature DB >> 20738007

Neuropsychologic testing for chemotherapy-related cognitive impairment.

Jamie S Myers1.   

Abstract

No standard has been established for neuropsychologic testing to identify and quantify chemotherapy-related cognitive impairment (CRCI). A number of issues exist related to the complexity of the phenomenon and lack of correlation between standardized objective tests and subjective tests by patient self-report. Review of the issues related to current neuropsychologic tests used to evaluate CRCI provides support for qualitative examination of patients' lived experience in order to guide the development of more accurate tests.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20738007     DOI: 10.1007/978-1-4419-6306-2_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

Review 1.  Stem cell therapies for the treatment of radiation-induced normal tissue side effects.

Authors:  Marc Benderitter; Fabio Caviggioli; Alain Chapel; Robert P Coppes; Chandan Guha; Marco Klinger; Olivier Malard; Fiona Stewart; Radia Tamarat; Peter van Luijk; Charles L Limoli
Journal:  Antioxid Redox Signal       Date:  2014-02-03       Impact factor: 8.401

Review 2.  Breast cancer medications and vision: effects of treatments for early-stage disease.

Authors:  Alvin Eisner; Shiuh-Wen Luoh
Journal:  Curr Eye Res       Date:  2011-08-05       Impact factor: 2.424

Review 3.  Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.

Authors:  Ana Dias-Carvalho; Mariana Ferreira; Rita Ferreira; Maria de Lourdes Bastos; Susana Isabel Sá; João Paulo Capela; Félix Carvalho; Vera Marisa Costa
Journal:  Arch Toxicol       Date:  2021-11-02       Impact factor: 5.153

4.  Review complementary and integrative interventions for cancer-related cognitive changes.

Authors:  Jamie S Myers
Journal:  Asia Pac J Oncol Nurs       Date:  2015-11-30

5.  Growth of malignant extracranial tumors alters microRNAome in the prefrontal cortex of TumorGraft mice.

Authors:  Anna Kovalchuk; Yaroslav Ilnytskyy; Rocio Rodriguez-Juarez; Amanda Katz; David Sidransky; Bryan Kolb; Olga Kovalchuk
Journal:  Oncotarget       Date:  2017-08-03

6.  Sex-specific effects of cytotoxic chemotherapy agents cyclophosphamide and mitomycin C on gene expression, oxidative DNA damage, and epigenetic alterations in the prefrontal cortex and hippocampus - an aging connection.

Authors:  Anna Kovalchuk; Rocio Rodriguez-Juarez; Yaroslav Ilnytskyy; Boseon Byeon; Svitlana Shpyleva; Stepan Melnyk; Igor Pogribny; Bryan Kolb; Olga Kovalchuk
Journal:  Aging (Albany NY)       Date:  2016-04       Impact factor: 5.682

7.  Attenuation of neuroinflammation reverses Adriamycin-induced cognitive impairments.

Authors:  Barrett D Allen; Lauren A Apodaca; Amber R Syage; Mineh Markarian; Al Anoud D Baddour; Harutyun Minasyan; Leila Alikhani; Celine Lu; Brian L West; Erich Giedzinski; Janet E Baulch; Munjal M Acharya
Journal:  Acta Neuropathol Commun       Date:  2019-11-21       Impact factor: 7.801

8.  Effect of Metformin on Doxorubicin-Induced Memory Dysfunction.

Authors:  Ibrahim Alharbi; Hindi Alharbi; Yasser Almogbel; Abdullah Alalwan; Ahmad Alhowail
Journal:  Brain Sci       Date:  2020-03-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.